Evidence map›Paper›PMID 29599381›Full record

ArticleBMJ case reports2018

Secondary mania following cancer chemotherapy with capecitabine.

Harshit Garg, Sathya Prakash, Koushik Sinha Deb, Rakesh Kumar Chadda

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Harshit GargDepartment of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
Sathya PrakashDepartment of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
Koushik Sinha DebDepartment of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
Rakesh Kumar ChaddaDepartment of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mania-like states occurring due to neurological, metabolic or toxic conditions, without a primary mood disorder have been reported in scientific literature as secondary mania. A major clinical problem in such situations often stems from the difficulty to understand if the mood disturbance is indeed secondary to an organic cause or a coincidental primary mood disorder. Chemotherapy regimens have been associated with multiple psychiatric complications, including psychosis, mania and anxiety. Capecitabine is implicated to be associated with encephalopathy whose clinical presentation often mimics that of psychosis. However, presentations with mania have not been reported until with the capecitabine and oxaliplatin combination chemotherapy regimen. In this report, we describe a case of secondary mania in a patient suffering from carcinoma colon on treatment with chemotherapy regimen of capecitabine and oxaliplatin.

Indexed as

Antimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsAntipsychotic AgentsBenzodiazepinesBipolar DisorderCapecitabineColonic NeoplasmsHumansMaleMiddle AgedOlanzapineOrganoplatinum CompoundsOxaliplatinAntimetabolites, AntineoplasticAntipsychotic AgentsBenzodiazepinesCapecitabineOlanzapineOrganoplatinum CompoundsOxaliplatinmalignant disease and immunosuppressionmood disorders (including depression)

Identifiers

PMID29599381
PMCPMC5878383
OpenAlexW2795067594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.